Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with KRAS wild-type metastatic colorectal cancer (mCRC): An Asia-Pacific nonrandomized phase II study (APEC).

被引：0
作者：
Cheng, Ann-Lii
Cornelio, Gerardo H.
Shen, Lin
Price, Timothy Jay
Yang, Tsai-Shen
Chung, Ik-Joo
Dai, Guanghai
Lin, Jen-Kou
Sharma, Atul
Yeh, Kun-Huei
Ma, Brigette
Zaatar, Adel
Guan, Zhongzhen
Masood, Nehal
Srimuninnimit, Vichien
Yau, Thomas Cheung
Sarholz, Barbara
Lim, Robert S. C.
机构：
[1] Natl Taiwan Univ Hosp, Taipei, Taiwan
[2] San Juan De Dios Hosp, Pasay City, Philippines
[3] Peking Univ, Canc Hosp, Minist Educ, Dept Gastrointestinal Oncol,Key Lab Carcinogenesi, Beijing 100871, Peoples R China
[4] Queen Elizabeth Hosp, Adelaide, SA, Australia
[5] Chang Gung Mem Hosp, Taoyuan, Taiwan
[6] Chonnam Natl Univ, Hawsun Hosp, Hwasuneup, South Korea
[7] Peoples Liberat Army, Gen Hosp, Beijing, Peoples R China
[8] Taipei Vet Gen Hosp, Taipei, Taiwan
[9] All India Inst Med Sci, New Delhi, India
[10] Chinese Univ Hong Kong, Prince Wales Hosp, Sha Tin, Hong Kong, Peoples R China
[11] Mt Miriam Canc Hosp, George Town, Malaysia
[12] Sun Yat Sen Univ, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China
[13] Aga Khan Univ & Hosp, Karachi, Pakistan
[14] Siriraj Hosp, Bangkok, Thailand
[15] Univ Hong Kong, Dept Surg, Hong Kong, Hong Kong, Peoples R China
[16] Merck KGaA, Darmstadt, Germany
[17] Natl Univ Hlth Syst, Singapore, Singapore
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14501
引用
收藏
页数：1
相关论文
共 50 条
[21]   Efficacy and safety of cetuximab, oxaliplatin, and capecitabine as first-line therapy for metastatic colorectal cancer (mCRC): Results of a phase II study [J].
Barroso, S. A. ;
Sanches, E. ;
Ferreira, M. ;
Passos, M. ;
Sa, A. ;
Nabico, R. ;
Sotto-Mayor, C. ;
Santo, J. Espirito ;
San-Bento, R. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[22]   A Phase II Study of XELOX and Cetuximab as First-Line Therapy in Patients With KRAS Wild Type Metastatic Colorectal Cancer (FLEET2 Study) [J].
Hazama, Shoichi ;
Maeda, Hiromichi ;
Iwamoto, Shigeyoshi ;
Kim, Ho Min ;
Takemoto, Hiroyoshi ;
Kobayashi, Kenji ;
Sakamoto, Junichi ;
Nagata, Naoki ;
Oba, Koji ;
Mishima, Hideyuki .
Clinical Colorectal Cancer, 2016, 15 (04) :329-336
[23]   FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study [J].
Brodowicz, T. ;
Ciuleanu, T. E. ;
Radosavljevic, D. ;
Shacham-Shmueli, E. ;
Vrbanec, D. ;
Plate, S. ;
Mrsic-Krmpotic, Z. ;
Dank, M. ;
Purkalne, G. ;
Messinger, D. ;
Zielinski, C. C. .
ANNALS OF ONCOLOGY, 2013, 24 (07) :1769-1777
[24]   A randomized, open-label CECOG phase II study evaluating the efficacy and safety of FOLFOX6+cetuximab versus FOLFIRI plus cetuximab as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC) [J].
Ciuleanu, T. E. ;
Kurteva, G. ;
Ocvirk, J. ;
Beslija, S. ;
Koza, I. ;
Papamichael, D. ;
Vrbanec, D. ;
Brodowicz, T. ;
Scheithauer, W. ;
Zielinski, C. C. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[25]   KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience [J].
Bokemeyer, C. ;
Bondarenko, I. ;
Hartmann, J. T. ;
De Braud, F. G. ;
Volovat, C. ;
Nippgen, J. ;
Stroh, C. ;
Celik, I. ;
Koralewski, P. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[26]   A phase I study of sorafenib with FOLFIRI as first-line therapy for metastatic colorectal cancer (mCRC): Safety and efficacy results [J].
Maroun, Jean Alfred ;
Jonker, Derek J. ;
Cripps, M. Christine ;
Asmis, Timothy R. ;
Goel, Rakesh ;
Goodwin, Rachel Anne ;
Marginean, Horia .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[27]   Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC) [J].
Ciuleanu, T. ;
Nikolic, V. ;
Shmueli, E. ;
Vrbanec, D. ;
Plate, S. ;
Krmpotic, Z. M. ;
Dank, M. ;
Purkaine, G. ;
Brodowicz, T. ;
Zielinski, C. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[28]   CETUXIMAB WEEKLY (Q1W) VERSUS EVERY TWO WEEKS (Q2W) PLUS FOLFOX4 AS FIRST-LINE THERAPY IN PATIENTS (PTS) WITH KRAS WILD-TYPE (WT) METASTATIC COLORECTAL CANCER (MCRC) [J].
Ciuleanu, Tudor ;
Nikolic, Vladimir ;
Shacham-Shmueli, Einat ;
Vrbanec, Damir ;
Plate, Signe ;
Mrsic-Krmpotic, Zrinka ;
Kahan, Zsuzsanna ;
Purkalne, Gunta ;
Brodowicz, Thomas ;
Zielinski, Christoph .
ANNALS OF ONCOLOGY, 2011, 22 :v22-v22
[29]   Cetuximab weekly (q1w) versus every two weeks (q2w) plus FOLFOX4 as first-line therapy in patients (pts) with KRAS wild-type (wt) metastatic colorectal cancer (mCRC). [J].
Ciuleanu, T. ;
Nikolic, V. ;
Shmueli, E. ;
Vrbanec, D. ;
Plate, S. ;
Krmpotic, Z. M. ;
Dank, M. ;
Purkalne, G. ;
Brodowicz, T. ;
Zielinski, C. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
[30]   Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancer [J].
Kasper, Stefan ;
Foch, Caroline ;
Messinger, Diethelm ;
Esser, Regina ;
Lamy, Francois-Xavier ;
Rothe, Vivien ;
Chen, Wenfeng ;
Cheng, Ann-Lii ;
Rouyer, Magali ;
Brodowicz, Thomas ;
Zielinski, Christoph .
EUROPEAN JOURNAL OF CANCER, 2021, 144 :291-301
12345